



Neuland Q1FY22 income at Rs.202.9 crore

EBITDA at Rs. 27.7 crore

Hyderabad, India, August 3, 2021 - Neuland Laboratories Limited (NLL) (NSE: NEULANLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the first quarter (Q1FY22) ended June 30, 2021.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, *“This quarter’s results are a one off in terms of performance. We witnessed inventory destocking from certain customers amid the pandemic, combined with certain business complexities resulting in revenue fluctuations. We believe that profitable operations amid this volatile quarter reflects the underlying strength of our business which I am confident will be further apparent over time.”*

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added *“Our R&D and production teams have been working on several complex projects in CMS business which require high degree of complexity and specialised execution. We are confident that our continued customer engagement for quality delivery will enable the CMS business to deliver scale and returns in the medium as well as long term.”*

Financial Summary

Rs. crore

Particulars	Q1FY22	Q4FY21	QoQ Growth (%)	Q1FY21	YoY Growth (%)
Total Income	202.9	259.3	(21.7)%	206.1	(1.5)%
EBITDA	27.7	40.0	(30.9)%	34.4	(19.7)%
EBITDA margin (%)	13.6%	15.4%	(180) bps	16.7%	(310) bps
PAT	8.6	17.2	(49.8)%	15.1	(42.6)%
PAT margin (%)	4.3%	6.6%	(230) bps	7.3%	(300) bps
EPS (Basic) Rs.	6.7	13.4	(49.8)%	11.7	(42.6)%

Q1 FY22 Earnings Call

The company will conduct a one-hour Earnings call at **17:00 hrs. IST on Tuesday, August 3, 2021** where the management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please register on the Zoom link below:

[Zoom Link](#)



Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 37 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs and has filed over 898+ Regulatory filings in the US (57 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID &GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 6761 1600

Email: ir@neulandlabs.com

Diwakar Pingle, Christensen

Email: dpingle@christensenir.com